The Venous Thromboembolism- Market Insights & Drugs Sales Forecast (VTE) -2020 report provides an overview of the disease, epidemiology and global market trends for the seven major markets ie: United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. According to DelveInsight, Global VTE market was $4.2 billion in 2015 and expected to grow to $4.75 billion by 2020 with a compound annual growth rate (CAGR) of 2.44%.
Globally the overall incidence for Venous Thromboembolism (VTE) is increasing at a higher rate. For VTE, there are approximately 1 million cases in the United States each year, many of which represent recurrent disease. The increasing epidemiology of venous thromboembolism is a key driver for the global anticoagulants market.
Key Coverage and Benefits:
• The report will help in developing business strategies by understanding the trends shaping and driving the global Venous Thromboembolism (VTE) market.
• Identifying patient populations in the global Venous Thromboembolism (VTE) market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the best opportunities for Venous Thromboembolism (VTE) therapeutics in each of the markets covered.
• To understand the future market competition in the global Venous Thromboembolism (VTE) therapeutics market and Insightful review of the key market drivers and barriers.
Scope of the Report:
• Report covers the disease overview including etiology, path physiology, symptoms, diagnosis, disease management, and current treatment options.
• Marketed information including available prescription drugs, its patent and exclusivity details followed by drug sales till 2018.
• The Report also covers the detailed global historical and forecasted epidemiological data covering United States, EU5, Japan and rest of the word from 2015-2020.
• It also provides Venous Thromboembolism (VTE) for United States, EU5 and Japan from 2015 and forecasted Market to 2020.
'
Table of Contents
Executive Summary
Market Share of Anticoagulants in 2015 and 2020
Worldwide Market Share of Anticoagulants in 2015
Worldwide Market Share of Anticoagulants in 2020
Chapter 1 Anticoagulants Introduction
Warfarin
Low Molecular Weight Heparins
New Oral Anticoagulants (NOAC)
Chapter 2 Venous Thromboembolism
Disease Overview
Epidemiology of Venous Thromboembolism
Treatment Landscape
Treatment Algorithm
Treatment Goals
Treatment Details
Chapter 3 Key Marketed Anticoagulants
Novel Oral Anticoagulants Comparison
Reversal Agents (Antidotes)
Chapter 4 Anticoagulants Market Assessment by VTE
Key Findings
Global Anticoagulants Market Sales by Venous Thromboembolism
Global Anticoagulants Market Share (%) in Venous Thromboembolism
Chapter 5 United States Anticoagulants Market Assessment
Key Findings
United States Anticoagulants Market Sales by Venous Thromboembolism
United States Anticoagulants Market Share (%) in Venous Thromboembolism
Chapter 6 Europe 5 Anticoagulants Market Assessment
Key Findings
Europe 5 Anticoagulants Market Sales by Venous Thromboembolism
Europe 5 Anticoagulants Market Share (%) in Venous Thromboembolism
Chapter 7 Japan Anticoagulants Market Assessment
Key Findings
Japan Anticoagulants Market Sales by Venous Thromboembolism
Japan Anticoagulants Market Share (%) in Venous Thromboembolism
Chapter 8 Xarelto (rivaroxaban) Drug Profile
Product Profile
Advantages & Disadvantages
Efficacy of Xarelto
Safety of Xarelto
Side effects of Drugs
Cost of Therapy
Global Drug Sales
Xarelto Historical Sales and Forecasted Sales (2011-2020)
Global Drug Sales by indication
Xarelto Historical Sales and Forecasted Sales (2011-2020) by VTE
Clinical Trials Information
SWOT Analysis of Xarelto
Chapter 9 Pradaxa (dabigatran etexilate mesylate) Drug Profile
Product Profile
Advantages & Disadvantages
Efficacy of Pradaxa
Safety of Pradaxa
Side effects of Drugs
Cost of Therapy
Global Drug Sales
Pradaxa Historical Sales and Forecasted Sales (2011-2020)
Global Drug Sales by indication
Pradaxa Historical Sales and Forecasted Sales (2011-2020) by VTE
Clinical Trial Information
SWOT Analysis of Pradaxa
Chapter 10 Eliquis(Apixaban) Drug Profile
Product Profile
Advantages & Disadvantages
Efficacy and Safety of Eliquis
Side effects of Eliquis
Cost of Therapy
Global Drug Sales
Eliquis Historical Sales and Forecasted Sales (2011-2020)
Global Drug Sales by indication
Eliquis Historical Sales and Forecasted Sales (2011-2020) by VTE
Clinical Trial Information
SWOT Analysis of Eliquis
Chapter 11 Savaysa (edoxaban tosylate) Drug Profile
Product Profile
Advantages & Disadvantages
Efficacy of Savaysa
Safety of Savaysa
Side Effects of Savaysa
Cost of Therapy
Global Drug Sales
Savaysa Historical Sales and Forecasted Sales (2011-2020)
Global Drug Sales by indication
Savaysa Historical Sales and Forecasted Sales (2011-2020) by VTE
Clinical Trial Information
SWOT Analysis of Savaysa
Chapter 12 Lovenox (enoxaparin) Drug Profile
Product Profile
Advantages & Disadvantages
Safety and Efficacy of Lovenox
Side effects of Lovenox
Cost of Therapy
Global Drug Sales
Lovenox Historical Sales and Forecasted Sales (2011-2020)
Global Drug Sales by indication (20%)
Lovenox Historical Sales and Forecasted Sales (2011-2020) by VTE
Clinical Trial Information
SWOT Analysis of Lovenox
Chapter 13 Fraxiparine
Product Profile
Advantages & Disadvantages
Safety and Efficacy of Fraxiparine
Side effects of Drugs
Cost of Therapy
Global Drug Sales
Fraxiparine Historical Sales and Forecasted Sales (2011-2020)
Global Drug Sales by indication
Fraxiparine Historical Sales and Forecasted Sales (2011-2020) by VTE
Clinical Trials Information
SWOT Analysis of Fraxiparine
Chapter 14 Arixtra (Fondaparinux) Drug Profile
Product Profile
Advantages & Disadvantages
Efficacy of Arixtra
Safety of Arixtra
Side effects of Drugs
Cost of Therapy
Global Drug Sales
Arixtra Historical Sales and Forecasted Sales (2011-2020)
Global Drug Sales by indication
Arixtra Historical Sales and Forecasted Sales (2011-2020) by VTE
Clinical Trial Information
SWOT Analysis of Arixtra
Chapter 15 Betrixaban Drug Profile
Product Profile
Advantages & Disadvantages
Safety and Efficacy
Side effects of Drugs
Expected Cost of Therapy
Global Drug Sales
Betrixaban Forecasted Sales (2011-2020)
Global Drug Sales by indication
Betrixaban Historical Sales and Forecasted Sales (2011-2020) by VTE
Clinical Trials Information
Chapter 16 Market Drivers and Constraints
Factors Driving the Market Growth
Factors Constraining the Market Growth
Consulting Services
Disclaimer
About DelveInsight
List of Tables
Table 1 Key Marketed Anticoagulants
Table 2 Comparison of NOACs & Warfarin
Table 3 Global Anticoagulants Sales in Venous Thromboembolism 2011-2020 (USD MM)
Table 4 Global Anticoagulants Sales in Venous Thromboembolism - 2015-2020 (USD MM)
Table 5 US Anticoagulants Sales in Venous Thromboembolism 2011-2020 (USD MM)
Table 6 US Anticoagulants Sales in Venous Thromboembolism - 2015-2020 (USD MM)
Table 7 EU5 Anticoagulants Sales in Venous Thromboembolism 2011-2020 (USD MM)
Table 8 EU5 Anticoagulants Sales in Venous Thromboembolism – 2015-2020 (USD MM)
Table 9 Japan Anticoagulants Sales in Venous Thromboembolism 2011-2020 (USD MM)
Table 10 Japan Anticoagulants Sales in Venous Thromboembolism - 2015-2020 (USD MM)
Table 11 Xarelto Historical Sales and Forecasted Sales (2011-2020)(USD MM)
Table 12 Xarelto Sales by Venous Thromboembolism (VTE) (USD MM)
Table 13 Xarelto, Clinical Trials by Zone, 2016
Table 14 Pradaxa Historical Sales and Forecasted Sales (2011-2020)(USD MM)
Table 15 Pradaxa Sales by Venous Thromboembolism (VTE) (USD MM)
Table 16 Pradaxa, Clinical Trials by Zone, 2016
Table 17 Eliquis Historical Sales and Forecasted Sales (2011-2020)(USD MM)
Table 18 Eliquis Sales by Venous Thromboembolism (VTE) (USD MM)
Table 19 Eliquis, Clinical Trials by Zone, 2016
Table 20Savaysa Historical Sales and Forecasted Sales (2011-2020)(USD MM)
Table 21 SavaysaSales by Venous Thromboembolism (VTE) (USD MM)
Table 22 Savaysa, Clinical Trials by Zone, 2016
Table 23 LovenoxHistorical Sales and Forecasted Sales (2011-2020)(USD MM)
Table 24 LovenoxSales by Venous Thromboembolism (VTE) (USD MM)
Table 25Lovenox, Clinical Trials by Zone, 2016
Table 26FraxiparineHistorical Sales and Forecasted Sales (2011-2020)(USD MM)
Table 27 FraxiparineSales by Venous Thromboembolism (VTE) (USD MM)
Table 28Fraxiparine, Clinical Trials by Zone, 2016
Table 29 ArixtraHistorical Sales and Forecasted Sales (2011-2020)(USD MM)
Table 30 ArixtraSales by Venous Thromboembolism (VTE) (USD MM)
Table 31Arixtra, Clinical Trials by Zone, 2016
Table 32BetrixabanForecasted Sales (2011-2020)(USD MM)
Table 33 BetrixabanSales by Venous Thromboembolism (VTE) (USD MM)
Table 34Betrixaban, Clinical Trials by Zone, 2016
List of Figures
Figure 1 Global Anticoagulants Sales in Venous Thromboembolism- 2011-2020
Figure 2 Global Anticoagulants Market Share (%) in Venous Thromboembolism - 2011-2020
Figure 3 US Anticoagulants Sales in Venous Thromboembolism- 2011-2020
Figure 4 US Anticoagulants Market Share (%) in Venous Thromboembolism - 2011-2020
Figure 5 EU5 Anticoagulants Sales in Venous Thromboembolism- 2011-2020
Figure 6 EU5 Anticoagulants Market Share (%) in Venous Thromboembolism - 2011-2020
Figure 7 Japan Anticoagulants Sales in Venous Thromboembolism- 2011-2020
Figure 8 Japan Anticoagulants Market Share (%) in Venous Thromboembolism - 2011-2020
Figure 9 Xarelto Historical Sales and Forecasted Sales (2011-2020) (USD MM)
Figure 10 Xarelto Sales by Venous Thromboembolism (VTE)(USD MM)
Figure 11 Xarelto, Clinical Trials by Zone (%), 2016
Figure 12 Pradaxa Historical Sales and Forecasted Sales (2011-2020) (USD MM)
Figure 13 Pradaxa Sales by Venous Thromboembolism (VTE)(USD MM)
Figure 14 Pradaxa, Clinical Trials by Zone (%), 2016
Figure 15 Eliquis Historical Sales and Forecasted Sales (2011-2020) (USD MM)
Figure 16 Eliquis Sales by Venous Thromboembolism (VTE)(USD MM)
Figure 17 Eliquis, Clinical Trials by Zone (%), 2016
Figure 18 SavaysaHistorical Sales and Forecasted Sales (2011-2020) (USD MM)
Figure 19 Savaysa Sales by Venous Thromboembolism (VTE)(USD MM)
Figure 20 Savaysa, Clinical Trials by Zone (%), 2016
Figure 21 Lovenox Historical Sales and Forecasted Sales (2011-2020) (USD MM)
Figure 22 Lovenox Sales by Venous Thromboembolism (VTE)(USD MM)
Figure 23 Lovenox, Clinical Trials by Zone (%), 2016
Figure 24 Fraxiparine Historical Sales and Forecasted Sales (2011-2020) (USD MM)
Figure 25 Fraxiparine Sales by Venous Thromboembolism (VTE)(USD MM)
Figure 26 Fraxiparine, Clinical Trials by Zone (%), 2016
Figure 27 ArixtraHistorical Sales and Forecasted Sales (2011-2020) (USD MM)
Figure 28 Arixtra Sales by Venous Thromboembolism (VTE)(USD MM)
Figure 29 Arixtra, Clinical Trials by Zone (%), 2016
Figure 30 BetrixabanForecasted Sales (2011-2020) (USD MM)
Figure 31 Betrixaban Sales by Venous Thromboembolism (VTE)(USD MM)
Figure 32 Betrixaban, Clinical Trials by Zone (%), 2016
Bayer
Janssen Pharmaceutica
Boehringer Ingelheim
Bristol-Myers Squib
Daiichi Sankyo
Sanofi-Aventis
Glaxosmithkline
Aspen Pharmaceuticals
Portola Pharmaceuticals
